Drugs / HHLivC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01195753 | Dec 2010 → Dec 2015 | urea cycle disorder | Cytonet GmbH & Co. KG | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HHLivC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195753 ↗ |
| Action | Restore | “supply a sufficient amount of healthy liver cells to compensate for the metabolic defect” NCT01195753 ↗ |
| Modality | Cell therapy | “repetitive application of human liver cells” NCT01195753 ↗ |